News First-in-class hay fever immunotherapy backed for NHS use A once-daily tablet that can help people suffering from hay fever caused by tree pollen, Alk-Abelló's Itulazax, has been recommended for NHS use.
News First intranasal anaphylaxis drug launches in Germany An alternative to epinephrine autoinjectors that can be delivered by a nasal spray has been launched in Germany, its first market, by ALK-Abello.
News Dust mite allergy sufferers set for a new NHS treatment ALK-Abello's Acarizax for dust mite allergy should soon be available through the NHS in England, Wales and Northern Ireland, but not in Scotland.
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.